Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 196Myelodysplastic Syndromes 128Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Leukemia, Lymphocytic, Chronic, B-Cell 102Leukemia 102Lymphoma 86Multiple Myeloma 81Lymphoma, Non-Hodgkin 80Hematologic Neoplasms 65Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62Hodgkin Disease 62Recurrence 52Lymphoma, B-Cell 40Lymphoma, Mantle-Cell 39Myeloproliferative Disorders 36Lymphoma, Follicular 35Melanoma 34Lymphoma, Large B-Cell, Diffuse 31Burkitt Lymphoma 31Graft vs Host Disease 28Neoplasms, Plasma Cell 24Primary Myelofibrosis 23Ovarian Neoplasms 23Lymphoma, B-Cell, Marginal Zone 23Anemia, Refractory, with Excess of Blasts 21Leukemia, Myelomonocytic, Chronic 20Leukemia, Biphenotypic, Acute 17Lymphoma, T-Cell 16Neuroblastoma 15Neoplasms 14

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesothelin-positive Advanced Refractory Solid Tumors × fludarabine × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡